Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Vosganian, G. S.
  • Bos, R.
  • Sherman, Linda

publication date

  • July 2012

journal

  • Journal of Immunotherapy  Journal

abstract

  • Vemurafenib is an orally available small molecule that targets constitutively activated BRAFV600E, an integral part of the MAPK pathway involved in melanomagenesis. We examined the effects of vemurafenib on cytokine production and antitumor response in a BRAF wild-type (WT) non-tumor-bearing murine model and a BRAF WT murine insulinoma system to determine its effect on immune function during immunotherapy. We demonstrate no significant effect from vemurafenib on CD4+ and CD8+ T-cell cytokine production or on a T-cell-mediated antitumor response. Our data demonstrate that vemurafenib does not significantly affect BRAF WT targets, suggesting that there may be a role for combining vemurafenib treatment with T-cell-directed immunotherapy.

subject areas

  • Animals
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Immunotherapy, Adoptive
  • Indoles
  • Insulinoma
  • Interferon-gamma
  • Interleukin-2
  • Melanoma
  • Mice
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
scroll to property group menus

Research

keywords

  • BRAF
  • immunotherapy
  • melanoma
  • murine model
  • vemurafenib
scroll to property group menus

Identity

PubMed Central ID

  • PMC3485086

International Standard Serial Number (ISSN)

  • 1524-9557

Digital Object Identifier (DOI)

  • 10.1097/CJI.0b013e3182618209

PubMed ID

  • 22735805
scroll to property group menus

Additional Document Info

start page

  • 473

end page

  • 477

volume

  • 35

issue

  • 6

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support